Thyrocare Technologies Ltd
NSE:THYROCARE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
559.95
985.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Thyrocare Technologies Ltd
Thyrocare Technologies Ltd
Cash & Cash Equivalents
Thyrocare Technologies Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Cash & Cash Equivalents
₹93m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Cash & Cash Equivalents
₹337.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
47%
|
CAGR 10-Years
26%
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Cash & Cash Equivalents
₹8.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Cash & Cash Equivalents
₹241.7m
|
CAGR 3-Years
53%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Cash & Cash Equivalents
₹535.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Cash & Cash Equivalents
₹712.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
What is Thyrocare Technologies Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
93m
INR
Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Cash & Cash Equivalents amounts to 93m INR.
What is Thyrocare Technologies Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-1%
Over the last year, the Cash & Cash Equivalents growth was -48%. The average annual Cash & Cash Equivalents growth rates for Thyrocare Technologies Ltd have been -11% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
